Other

U.S. tax on foreign earnings, net of credits

Vertex Pharmaceuticals U.S. tax on foreign earnings, net of credits remained flat by 0.0% to -3.1% in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 1900.0%, from 0.2% to -3.1%. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement
SectionOther
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2024Feb 13, 2026

How to read this metric

Lower costs indicate more efficient management of foreign earnings and tax credit utilization.

Detailed definition

This metric measures the U.S. tax impact on foreign earnings, net of applicable foreign tax credits. It reflects the tax...

Peer comparison

Standard metric for U.S.-based multinationals to reconcile global tax burdens.

Metric ID: other_effective_income_tax_rate_reconciliation_repatriat_10b517

Historical Data

2 years
 FY'23FY'24
Value0.7%-12.6%
YoY Change<-999%
Range-12.6%0.7%
Avg YoY Growth<-999%
Median YoY Growth<-999%

Frequently Asked Questions

What is Vertex Pharmaceuticals's u.s. tax on foreign earnings, net of credits?
Vertex Pharmaceuticals (VRTX) reported u.s. tax on foreign earnings, net of credits of -3.1% in Q4 2024.
How has Vertex Pharmaceuticals's u.s. tax on foreign earnings, net of credits changed year-over-year?
Vertex Pharmaceuticals's u.s. tax on foreign earnings, net of credits decreased by 1900.0% year-over-year, from 0.2% to -3.1%.
What does u.s. tax on foreign earnings, net of credits mean?
The net tax cost or benefit of taxing foreign earnings in the U.S. after accounting for credits.